TABLE 2.
Treatment-emergent adverse events assessed as related to study treatment by the blinded site investigator following a single dose of placebo or sutezolida
| Preferred term | Placebo (n = 8) | Sutezolid, 300 mg (n = 6) | Sutezolid, 600 mg (n = 6) | Sutezolid, 1,200 mg (n = 6) | Sutezolid, 1,800 mg (n = 6) |
|---|---|---|---|---|---|
| Abdominal distension | 0 | 0 | 0 | 0 | 1 |
| Abdominal pain | 0 | 0 | 0 | 1 | 0 |
| Myalgia | 0 | 0 | 0 | 0 | 1 |
| Postural orthostatic tachycardia syndrome | 2 | 1 | 0 | 1 | 1 |
| Transaminases increased | 0 | 0 | 0 | 1 | 0 |
a
Each cohort consisted of six subjects who took active drug (sutezolid) and two subjects who took placebo. n = number of subjects administered placebo or sutezolid in each dosing group.